Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Non-Current Assets (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Non-Current Assets data on record, last reported at $389000.0 in Q3 2025.

  • For Q3 2025, Non-Current Assets fell 64.64% year-over-year to $389000.0; the TTM value through Sep 2025 reached $2.7 million, down 49.84%, while the annual FY2024 figure was $944000.0, 39.45% down from the prior year.
  • Non-Current Assets reached $389000.0 in Q3 2025 per BTAI's latest filing, down from $546000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $3.5 million in Q1 2022 and bottomed at $389000.0 in Q3 2025.
  • Average Non-Current Assets over 4 years is $1.8 million, with a median of $1.6 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: dropped 18.6% in 2023, then crashed 64.64% in 2025.
  • A 4-year view of Non-Current Assets shows it stood at $3.0 million in 2022, then tumbled by 47.77% to $1.6 million in 2023, then crashed by 39.45% to $944000.0 in 2024, then tumbled by 58.79% to $389000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $389000.0 in Q3 2025, $546000.0 in Q2 2025, and $789000.0 in Q1 2025.